Drug Allergy A Guide to Diagnosis and Management

Size: px
Start display at page:

Download "Drug Allergy A Guide to Diagnosis and Management"

Transcription

1 Drug Allergy A Guide to Diagnosis and Management (Version 1 April 2015 updated April 2018) Author: Jed Hewitt Chief Pharmacist, Governance & Professional Practice Date of Preparation: April 2015 Updated: April 2018 Date for next full Review: April 2021 Approved by the Trust Drugs & Therapeutics Group in April 2015 If you require this document in an alternative format, ie, easy read, large text, audio, Braille or a community language please contact the Pharmacy Team on (Text Relay calls welcome)

2 1. Introduction. 1.1 All drugs have the potential to cause side effects, also known as 'adverse drug reactions', but not all of these are allergic in nature. Other reactions are idiosyncratic, pseudo-allergic or caused by drug intolerance. The British Society for Allergy and Clinical Immunology (BSACI) defines drug allergy as an adverse drug reaction with an established immunological mechanism. The mechanism at presentation may not be apparent from the clinical history and it cannot always be established whether a drug reaction is allergic or non-allergic without investigation. This guidance defines drug allergy as any reaction caused by a drug with clinical features compatible with an immunological mechanism. 1.2 The commonest drug allergies are in response to antibiotics, (in particular peniciliins and cephalosporins) and non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin. However, drug allergies are not as common as often believed. Whilst 10% of the general population claim to have penicillin allergy, in reality less than 1% are truly allergic. 1.3 Allergic reactions to NSAIDs are much more common in those with asthma. 1.4 Drug allergy to psychotropic drugs is rare but is more commonly seen in response to anticonvulsant drugs. 2. Prevention. 2.1 Prevention of drug allergy is achieved by avoiding exposure to drugs for which the patient has known allergy or sensitivity and to those for which crosssensitivity is possible. This applies to prescribed medication and for those purchased without prescription. 2.2 When prescribing, great care must be taken to avoid prescribing drugs for which there is known patient allergy. Information sources for drug allergy status include: Medical notes Medical letters from specialist centres GP patient summaries Summary Care Records The patient The patient s carers / relatives 2.3 Ideally, allergy status should be confirmed before the first drug chart is completed on admission. 2.4 Allergy status or sensitivities to medication must be recorded on the drug chart, (inpatient and/or community long-acting injection chart), ideally by the prescriber when first completing the chart. If this cannot be ascertained at the time of first writing up the chart the prescriber must complete the second section of the allergy box (inpatient chart) stating the allergy status is not yet ascertained. The medical team is ultimately responsible for completing the allergy status box as

3 soon as possible, but another healthcare clinician involved in the medicines management process may ascertain the status and sign instead of the prescriber, including their designation e.g. pharmacist. 2.5 When rewriting drug charts, allergies or sensitivities must be carried forward. 2.6 If there is a known allergy, the following signed and dated entries must be made in the patient s notes and on all drug charts: Generic name(s) of medicine(s), unless otherwise recommended by the BNF Nature of reaction(s) to ensure a true allergy is being described. 2.7 When administering medication it is vital that the allergy status of the patient be checked on every occasion, especially in relation to newly prescribed medication. If allergy status is not recorded, every attempt should be made to ascertain and record this prior to administration. 2.8 Further to point 2.7, if a penicillin has been prescribed for a patient whose allergy status is not recorded, administration should not take place until the relevant information has been obtained and recorded. 3. Assessment Signs & allergic patterns of suspected allergy 3.1 When assessing a person presenting with a possible drug allergy, take a history and undertake a clinical examination. (The following boxes can be used as a guide when deciding whether to suspect drug allergy). Box 1 Immediate, rapidly evolving reactions: Anaphylaxis a severe multi-system reaction characterised by: erythema, urticaria or angioedema and hypotension and/or bronchospasm Onset is usually within an hour of drug exposure. (Previous exposure not always confirmed). Urticaria or angioedema without systemic features Exacerbation of asthma (eg. with NSAIDs). Glossary see section 11.

4 Box 2 Non-immediate reactions without systemic involvement: Widespread red macules or papules (exanthema-like) Fixed drug eruption (localised inflamed skin) Onset usually 6 to 10 days after first drug exposure or within 3 days of second exposure. Box 3 Non-immediate reactions with systemic involvement: Drug reaction with eosinophilia and systemic symptoms (DRESS) or drug hypersensitivity syndrome (DHS) characterised by: Onset usually 2 to 6 weeks after first drug exposure or within 3 days of second exposure. widespread red macules, papules or erythroderma fever lymphadenopathy liver dysfunction eosinophilia Toxic epidermal necrolysis or Stevens- Johnson syndrome characterised by: painful rash and fever mucosal or cutaneous erosions vesicles, blistering or epidermal detachment red purpuric macules or erythema multiforme Acute generalised exanthematous pustulosis ( AGEP) characterised by: Onset usually 7 to 14 days after first drug exposure or within 3 days of second exposure. Onset usually 3 to 5 days after first exposure. widespread pustules fever neutrophilia Common disorders caused, rarely, by drug allergy: Variable time of onset. eczema hepatitis nephritis vasculitis photosensitivity Glossary see section 11.

5 3.2 Clinicians should be aware that a reaction is more likely to be caused by drug allergy if it occurs during or after use of the drug and: the drug is known to cause that type of reaction the patient has previously had a similar reaction to the same drug or to another drug in the same class 3.3 Clinicians should be aware that a reaction is less likely to be caused by drug allergy if: there is a possible non-drug cause for the patient s symptoms eg. they have had similar symptoms when not taking the drug - or the patient only has gastrointestinal symptoms. 4. Documenting and sharing information. 4.1 Patients drug allergy status must be clearly recorded in their medical record. 4.2 Patients drug allergy status must also be recorded on the front of their drug chart(s) using the dedicated allergy box. This must be recorded on each chart in use and always be carried forward when new charts are started. 4.3 If there is a drug allergy, the following minimum information must be recorded: the (generic) drug name the signs, symptoms and severity of the reaction the date when the reaction first occurred (if known) 5. Documenting new suspected drug reactions 5.1 When a patient presents with a suspected drug allergy, the reaction must be clearly recorded in the medical notes including: the generic (and proprietary) name of the drug suspected of causing the reaction the strength, formulation and route of the drug a description of the reaction see section 3 the diagnosis / illness the drug was being taken for the date and time of the reaction the number of doses taken or the number of days on the drug before the onset of the reaction 5.2 The patient s GP should be consulted / informed at the earliest opportunity. 6. Maintaining and sharing drug allergy information 6.1 Drug allergy status should be documented separately from adverse drug reaction information so that it remains clearly visible to all prescribers.

6 6.2 Where possible, patients drug allergy status should be confirmed with the patient or with their carers before prescribing or administering any drug. Alternative information sources such as Summary Care Records and GP Summaries should also be used routinely. 6.3 Confirmation of drug allergy status must be considered a routine part of medicines reconciliation at the time of admission to any inpatient unit. 6.4 Information about allergy status must be kept updated and must be included in all hospital discharge letters, specialist referral letters and GP referral letters. 7. Providing information and support to patients 7.1 Clinicians must ensure patients (and their carers) are aware of the drugs or drug classes that they need to avoid. They should be advised to check with the pharmacist before taking any over-the-counter medicines. 7.2 Clinicians should advise patients (and their carers) to carry information about their drug allergy with them at all times and to share this with any healthcare professional that is treating them, eg. hospital doctor, GP, dentist, pharmacist, nurse. 8. Non-specialist management and referral to specialist services 8.1 If a drug allergy is suspected: Consider stopping the drug(s) suspected to have caused it and advise the patient that they should avoid that drug in the future. Where possible, treat the symptoms of the acute reaction if not severe. Send patients with a severe reaction to the nearest casualty department, by ambulance if necessary. Fully document the incident in the patient s medical notes see section 5. When appropriate, provide the patient (and their carers) with the information. 8.2 If a patient has an anaphylactic reaction they should still be immediately referred to the nearest casualty department (dial 999), even if the reaction appears to have been successfully treated by administering adrenaline injection. 8.3 Following an anaphylactic reaction, Trust services should follow up with acute hospital services to ensure the patient receives a referral to a specialist drug allergy service. This should also occur following any severe non-immediate cutaneous reaction eg, Stevens-Johnson syndrome or epidermal necrosis.

7 9. Non-steroidal anti-inflammatory drugs (NSAIDs) 9.1 If patients have had a mild allergic reaction to a NSAID but still need an antiinflammatory, consideration can be given to using a selective COX-II inhibitor (eg. celecoxib), as these carry a lower risk of allergy. However, those prescribing and administering must remain aware that there is still some risk of cross sensitivity, so a low starting dose should be used and administration should only be once daily. 10. Beta-lactam antibiotics eg. penicillins, cephalosporins 10.1 Patients with a suspected drug allergy to a beta-lactam antibiotic should be referred to a specialist drug allergy service if: they need treatment for an illness that can only be treated by beta-lactam antibiotic, and/or they are likely to need a beta-lactam antibiotic frequently in the future. 11. Glossary Angioedema Epidermal necrolysis Eosinophilia Erythema Erythroderma Exanthema Lymphadenopathy Macules Nephritis Papules Pustules Urticaria Vasculitis Swelling of skin and/or mucous membranes Potentially life-threatening separation of skin layers Raised eosinophil count (>450µL) Redness of skin and/or mucous membranes Widespread inflammation of the skin Widespread rash Swollen lymph glands (or other abnormality) Flat discoloured areas of skin Inflammation of the kidneys Raised discoloured areas of skin Small, fluid-filled skin eruptions Raised itchy rash Inflammation of blood vessels Reference: NICE Clinical Guideline 183 (September 2014): Drug allergy diagnosis and management in adults, children and young people. Cross reference: Trust Medicines Code (2017/18) Section 4.

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

PedsCases Podcast Scripts

PedsCases Podcast Scripts PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Drug Allergy. These podcasts are designed to give medical students an overview of key topics in pediatrics. The audio

More information

Policy for the Treatment of Anaphylaxis in Adults and Children

Policy for the Treatment of Anaphylaxis in Adults and Children Policy for the Treatment of Anaphylaxis in Adults and Children June 2008 Policy Title: Policy for the Treatment of Anaphylaxis in Adults or Children Policy Reference Number: PrimCare08/17 Implementation

More information

Emergency Dermatology Dr Melissa Barkham

Emergency Dermatology Dr Melissa Barkham Emergency Dermatology Dr Melissa Barkham Spotlight Seminar 30 th September 2010 Why is this important? Urgent recognition and treatment of dermatologic emergencies can be life saving and prevent long term

More information

Emergency Dermatology. Emergency Dermatology

Emergency Dermatology. Emergency Dermatology Emergency Dermatology These are rapidly progressive skin conditions and some are potentially lifethreatening. Early recognition is important to implement prompt supportive care and therapy. Some are drug

More information

New product information wording Extracts from PRAC recommendations on signals

New product information wording Extracts from PRAC recommendations on signals 12 October 2017 EMA/PRAC/610988/2017 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording Extracts from PRAC recommendations on signals Adopted at the 25-29 September 2017

More information

Skin Manifestations of Drug Reactions

Skin Manifestations of Drug Reactions Skin Manifestations of Drug Reactions Dr Carol Hlela, Division of Dermatology Department of Medicine, University of Cape Town and Red Cross Children s Hospital What are the Skin Manifestations of Drug

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Dalacin C 150mg Capsules clindamycin hydrochloride PFIZER Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen

More information

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of

More information

Food allergy in children. nice bulletin. NICE Bulletin Food Allergy in Chlidren.indd 1

Food allergy in children. nice bulletin. NICE Bulletin Food Allergy in Chlidren.indd 1 nice bulletin Food allergy in children NICE provided the content for this booklet which is independent of any company or product advertised NICE Bulletin Food Allergy in Chlidren.indd 1 23/01/2012 11:04

More information

Adverse drug reactions

Adverse drug reactions Medications William Smith Adverse drug reactions Allergy? Side-effect? Intolerance? Background Adverse drug reactions (ADRs) vary from life-threatening anaphylaxis to minor common side-effects. Objective

More information

Cutaneous Drug Reactions

Cutaneous Drug Reactions Cutaneous Drug Reactions Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada Copyright 2017 by Sea Courses

More information

Dalacin C 150 mg Hard Capsules Clindamycin (as clindamycin hydrochloride)

Dalacin C 150 mg Hard Capsules Clindamycin (as clindamycin hydrochloride) Package leaflet: Information for the patient Dalacin C 150 mg Hard Capsules Clindamycin (as clindamycin hydrochloride) Read all of this leaflet carefully before you start taking this medicine because it

More information

MANAGING COMMON PRESENTATIONS OF ALLERGY IN PRIMARY CARE. Helen Bourne Consultant Immunologist

MANAGING COMMON PRESENTATIONS OF ALLERGY IN PRIMARY CARE. Helen Bourne Consultant Immunologist MANAGING COMMON PRESENTATIONS OF ALLERGY IN PRIMARY CARE Helen Bourne Consultant Immunologist AIMS Presentation of Allergic Disease in Adults Rhinitis/ Rhinoconjuctivitis Urticaria and Angioedema Food

More information

Drug Allergy HSJ 19/09/2011

Drug Allergy HSJ 19/09/2011 Drug Allergy HSJ 19/09/2011 BSACI Guidelines Definitions Mechanisms Clinical Features Risk factors Diagnosis Investigations Criteria for referral/investigation Mirakian et al. Clin Exp All 2008 ; 39: 43-61

More information

Document Details. Patient Group Direction

Document Details. Patient Group Direction Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute

More information

8/8/2016. Overview. Back to Basics: Immunology. Adverse Reactions to Drugs: Dispelling Myths

8/8/2016. Overview. Back to Basics: Immunology. Adverse Reactions to Drugs: Dispelling Myths Adverse Reactions to Drugs: Dispelling Myths Allison Ramsey, MD NPA Annual Conference September 30, 2016 Overview Review of types of hypersensitivity reactions Penicillin allergy IV contrast allergy Local

More information

VI.2 Elements for a public summary. VI.2.1 Overview of disease epidemiology

VI.2 Elements for a public summary. VI.2.1 Overview of disease epidemiology VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Sinus infection (Acute bacterial sinusitis) Sinus infection (upper respiratory infection) is short-lived infection of the sinuses,

More information

Herbal and homeopathic products, often considered natural and non-toxic, can also cause adverse drug reactions.

Herbal and homeopathic products, often considered natural and non-toxic, can also cause adverse drug reactions. Idiosyncratic and potentially serious cutaneous adverse drug reactions (CADRs), although relatively rare, account for significant morbidity and mortality. RANNAKOE J LEHLOENYA, BSc, MB ChB, FCDerm (SA)

More information

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version

More information

Managing Penicillin Allergy

Managing Penicillin Allergy Managing Penicillin Allergy Brian T. Kelly, MD MA April 12, 2019 Objectives Review penicillin allergy prevalence, morbidity, and management Describe the penicillin testing and oral challenge process Provide

More information

An unpredictable, dose-independent adverse drug reaction which is immunologically or IgEmediated.

An unpredictable, dose-independent adverse drug reaction which is immunologically or IgEmediated. R H E U M A T I S M D I S O R D E R S A N D A L L E R G I E S APPROACH TO DRUG ALLERGY Dr Bernard Thong DEFINITION OF DRUG ALLERGY An unpredictable, dose-independent adverse drug reaction which is immunologically

More information

PROCEDURE FOR MANAGING AN ANAPHYLACTIC EMERGENCY

PROCEDURE FOR MANAGING AN ANAPHYLACTIC EMERGENCY MULTIDISCIPLINARY PROCEDURE PROCEDURE FOR MANAGING AN ANAPHYLACTIC EMERGENCY First Issued June 2011 Issue Version Four Purpose of Issue/Description of Change Planned Review Date To promote safe and consistent

More information

ANTIBIOTICS ACUTE RHINOSINUSITIS IN CHILDREN

ANTIBIOTICS ACUTE RHINOSINUSITIS IN CHILDREN MARCH 2016 DRUG ANTIBIOTICS This optimal usage guide is mainly intended f primary care health professionnals. It is provided f infmation purposes only and should not replace the clinician s judgement.

More information

Antibiotic allergy in the Intensive Care. Sanjay Swaminathan Clinical Immunologist, Westmead and Blacktown Hospitals September 28, 2017

Antibiotic allergy in the Intensive Care. Sanjay Swaminathan Clinical Immunologist, Westmead and Blacktown Hospitals September 28, 2017 Antibiotic allergy in the Intensive Care Sanjay Swaminathan Clinical Immunologist, Westmead and Blacktown Hospitals September 28, 2017 Outline of talk True or false? Case example Types of drug allergy

More information

Tony Gray Head of Safety and Security. Tony Gray Head of Safety and Security. Contents Section Description Page No.

Tony Gray Head of Safety and Security. Tony Gray Head of Safety and Security. Contents Section Description Page No. Health and Safety Policy Practice Guidance Note Latex Sensitivity V04 Date Issued Planned Review Issue 1 Oct 17 Oct 2020 HS-PGN-10 Part of NTW(O)20 Health and Safety Policy Author/Designation Tony Gray

More information

Title Management of Impetigo Protocol in MIUs and WICs. Author s job title Professional Lead, Minor Injuries Unit Directorate

Title Management of Impetigo Protocol in MIUs and WICs. Author s job title Professional Lead, Minor Injuries Unit Directorate Document Control Title Management of Impetigo Protocol in MIUs and WICs Author Author s job title Professional Lead, Minor Injuries Unit Directorate Department MIU Version Date Issued Status Comment /

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Feldene 5mg/g Gel Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram contains 5 mg piroxicam (0.5% w/w). Excipient with known effect:

More information

REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES. R e g i S C A R PATIENT'S DATA. Age country of birth

REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES. R e g i S C A R PATIENT'S DATA. Age country of birth REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES R e g i S C A R PATIENT'S DATA Initials of the patient date of birth Age country of birth Gender male female

More information

Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)

Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated

More information

Title: Cutaneous Adverse Drug Reactions in Indian population: A systematic review

Title: Cutaneous Adverse Drug Reactions in Indian population: A systematic review Title: Cutaneous Adverse Drug Reactions in Indian population: A systematic review Review question(s) To carry out a systematic review of the published evidence of the cutaneous adverse drug reactions in

More information

Package leaflet: Information for the user. Floxapen 250 mg & 500 mg Capsules. Flucloxacillin

Package leaflet: Information for the user. Floxapen 250 mg & 500 mg Capsules. Flucloxacillin Package leaflet: Information for the user Floxapen 250 mg & 500 mg Capsules Flucloxacillin Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

A Retrospective Cross- sectional Study Evaluating Beta- lactam Allergy Labeling in Hospitalized Patients

A Retrospective Cross- sectional Study Evaluating Beta- lactam Allergy Labeling in Hospitalized Patients Pharmacy Residency Research Project Manuscript A Retrospective Cross- sectional Study Evaluating Beta- lactam Allergy Labeling in Hospitalized Patients Bingjie (Amy) Wang Pharmacy Resident Trillium Health

More information

Penicillin Allergy and Use of Other Antibiotics

Penicillin Allergy and Use of Other Antibiotics Penicillin Allergy and Use of Other Antibiotics 7300-646PT Policy No.: 7310-646PT 8790-646PT Original Policy Date: 10/10/2016 Revision Date(s): Review Date(s): Approval: 11/17/16 Pharmacy & Therapeutics

More information

The mechanisms of common drug hypersensitivities and implications for testing

The mechanisms of common drug hypersensitivities and implications for testing The mechanisms of common drug hypersensitivities and implications for testing R J Heddle 17 May 2016 Adverse Drug Reactions (ADR) Type A 85-90% of ADR Any individual, given sufficient dose & exposure Predictable

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin 250 mg Tablets sodium fusidate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

More information

New product information wording Extracts from PRAC recommendations on signals

New product information wording Extracts from PRAC recommendations on signals 20 July 2017 EMA/PRAC/406976/2017 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording Extracts from PRAC recommendations on signals Adopted at the 3-6 July 2017 PRAC The

More information

patient group direction

patient group direction ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

Cutaneous Adverse Drug Reactions in Domestic Animals. Katherine Doerr, DVM, Dip. ACVD. Veterinary Dermatology Center

Cutaneous Adverse Drug Reactions in Domestic Animals. Katherine Doerr, DVM, Dip. ACVD. Veterinary Dermatology Center Cutaneous Adverse Drug Reactions in Domestic Animals Katherine Doerr, DVM, Dip. ACVD Veterinary Dermatology Center Maitland, Rockledge, Waterford Lakes, FL Not highly studied in veterinary medicine Unknown

More information

DERMATOLOGIC EMERGENCIES. Mary Evers D.O., F.A.O.C.D. Georgetown, Texas

DERMATOLOGIC EMERGENCIES. Mary Evers D.O., F.A.O.C.D. Georgetown, Texas DERMATOLOGIC EMERGENCIES Mary Evers D.O., F.A.O.C.D. Georgetown, Texas SKIN EMERGENCIES??? Subclassifications: Autoimmune (Anaphylaxis, Vasculitis, Pemphigus) Erythroderma (AGEP, DRESS, SJS, TEN) Infectious

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin 250 mg/5 ml Oral Suspension fusidic acid Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

patient group direction

patient group direction NAPROXEN v01 1/10 NAPROXEN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

AUSTRAPEN ampicillin (as sodium)

AUSTRAPEN ampicillin (as sodium) AUSTRAPEN ampicillin (as sodium) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about AUSTRAPEN. It does not contain all the available information. It

More information

Appropriate prescribing of specialist infant formula feeds

Appropriate prescribing of specialist infant formula feeds Appropriate Prescribing of Specialist Infant Formula Feeds Purpose of the guidance These guidelines aim to assist GPs and Health Visitors with information on the appropriate use of infant formula that

More information

Diagnosis and management of suspected drug allergies

Diagnosis and management of suspected drug allergies Diagnosis and management of suspected drug allergies SPL Sophie Farooque MRCP Allergic reactions can be caused by commonly prescribed drugs and can lead to fatal anaphylaxis. Here, the author describes

More information

Package leaflet: Information for the user. Piperacillin/Tazobactam Actavis 4 g / 0.5 g powder for solution for infusion. piperacillin / tazobactam

Package leaflet: Information for the user. Piperacillin/Tazobactam Actavis 4 g / 0.5 g powder for solution for infusion. piperacillin / tazobactam Package leaflet: Information for the user Piperacillin/Tazobactam Actavis 2 g / 0.25 g powder for solution for infusion Piperacillin/Tazobactam Actavis 4 g / 0.5 g powder for solution for infusion piperacillin

More information

Title Protocol for Insect Bites Stings for Patients in MIUs and WICs

Title Protocol for Insect Bites Stings for Patients in MIUs and WICs Document Control Title Protocol for Insect Bites Stings for Patients in MIUs and WICs Author Author s job title Professional Lead, Minor Injuries Unit Directorate, Logistics and Resilience Department Emergency

More information

פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר SUMMARY OF PRODUCT CHARACTERISTICS

פורמט עלון זה נקבע עי משרד הבריאות ותוכנו נבדק ואושר SUMMARY OF PRODUCT CHARACTERISTICS פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT FELDENE GEL 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram contains 5mg

More information

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET PATIENT INFORMATION LEAFLET Oramox (Amoxicillin Oral Suspension BP) 125mg/5ml Oramox (Amoxicillin Oral Suspension BP) 250mg/5ml Amoxicillin (as amoxicillin trihydrate) Read all of this leaflet carefully

More information

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance

More information

GROUP PROTOCOL FOR THE MANAGEMENT OF SYMPTOMS OF COUGHS. Version 5 December 2017

GROUP PROTOCOL FOR THE MANAGEMENT OF SYMPTOMS OF COUGHS. Version 5 December 2017 GROUP PROTOCOL FOR THE MANAGEMENT OF SYMPTOMS OF COUGHS Version 5 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse MAUP

More information

patient group direction

patient group direction NITROFURANTOIN v01 1/12 NITROFURANTOIN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

Medical Documentation/Records. ADVERSE DRUG REACTIONS (ADRs) AND ALLERGIES TO MEDICATIONS

Medical Documentation/Records. ADVERSE DRUG REACTIONS (ADRs) AND ALLERGIES TO MEDICATIONS FLORIDA STATE HOSPITAL OPERATING PROCEDURE NO. 151-24 STATE OF FLORIDA DEPARTMENT OF CHILDREN AND FAMILIES CHATTAHOOCHEE, April 26, 2017 Medical Documentation/Records ADVERSE DRUG REACTIONS (ADRs) AND

More information

Anaphylaxis: Treatment in the Community

Anaphylaxis: Treatment in the Community : Treatment in the Community is likely if a patient who, within minutes of exposure to a trigger (allergen), develops a sudden illness with rapidly progressing skin changes and life-threatening airway

More information

Package leaflet: Information for the patient. Azithran 500 mg film coated tablet. azithromycin

Package leaflet: Information for the patient. Azithran 500 mg film coated tablet. azithromycin Package leaflet: Information for the patient Azithran 500 mg film coated tablet azithromycin Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Package leaflet: Information for the patient. Bromhexin Krewel Meuselbach Drops 12 mg/ml. Bromhexine hydrochloride

Package leaflet: Information for the patient. Bromhexin Krewel Meuselbach Drops 12 mg/ml. Bromhexine hydrochloride Package leaflet: Information for the patient Bromhexin Krewel Meuselbach Drops 12 mg/ml Bromhexine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains

More information

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride Package leaflet: Information for the patient / / 30 mg/5 ml syrup Ambroxol hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Package Leaflet: Information for the User. Clonamox 125 mg/5 ml Powder for Oral Suspension Clonamox 250 mg/5 ml Powder for Oral Suspension

Package Leaflet: Information for the User. Clonamox 125 mg/5 ml Powder for Oral Suspension Clonamox 250 mg/5 ml Powder for Oral Suspension Package Leaflet: Information for the User Clonamox 125 mg/5 ml Powder for Oral Suspension Clonamox 250 mg/5 ml Powder for Oral Suspension Amoxicillin Read all of this leaflet carefully before you start

More information

PROFESSIONAL INFORMATION

PROFESSIONAL INFORMATION SCHEDULING STATUS: S1 PROPRIETARY NAME AND DOSAGE FORM: Aleve Tablets COMPOSITION: Each tablet contains naproxen sodium 220 mg (equivalent to 200 mg naproxen) CATEGORY AND CLASS: A / 2.7 Antipyretic or

More information

Package leaflet: Information for the patient. ZITHROMAX 250 mg Capsules azithromycin

Package leaflet: Information for the patient. ZITHROMAX 250 mg Capsules azithromycin Package leaflet: Information for the patient ZITHROMAX 250 mg Capsules azithromycin Read all of this leaflet carefully before you start taking this medicine because it contains important information for

More information

Pediatric Dermatology

Pediatric Dermatology Pediatric Dermatology --------- Emergencies & Urgencies Nicholas V. Nguyen, M.D. Director, Pediatric Dermatology Disclosures In the past 12 months, I have had the following financial relationships with

More information

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis

More information

PATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )

PATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) PATIENT GROUP DIRECTION Administration of: Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) By: Practice Nurses In: General Practice It is the responsibility of the professional working under

More information

Anaphylaxis ASCIA Education Resources Information for health professionals

Anaphylaxis ASCIA Education Resources Information for health professionals Anaphylaxis ASCIA Education Resources Information for health professionals Anaphylaxis is a rapidly evolving, generalised multi-system allergic reaction characterized by one or more symptoms or signs of

More information

Methotrexate for inflammatory bowel disease: what you need to know

Methotrexate for inflammatory bowel disease: what you need to know Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or

More information

Drug induced allergy and hypersensitivity

Drug induced allergy and hypersensitivity Drug induced allergy and hypersensitivity Yunita Sari Pane, Aznan Lelo Dept. Pharmacology & Therapeutic School of Medicine Universitas Sumatera Utara 13 Mei 2009, KBK-FK USU, Medan Drug Allergy Adverse

More information

Ketorolac injection. Supportive care

Ketorolac injection. Supportive care Supportive care Ketorolac injection Supportive care: specialist medicines This leaflet provides information on a medicine called ketorolac which is used to treat pain that is difficult to control. It is

More information

patient group direction

patient group direction REVAXIS v01 1/12 REVAXIS (DIPHTHERIA, TETANUS AND POLIOMYELITIS (INACTIVATED) VACCINE (ADSORBED, REDUCED ANTIGEN(S) CONTENT)) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic

More information

Tacrolimus. Information for patients about using the drug Tacrolimus.

Tacrolimus. Information for patients about using the drug Tacrolimus. Tacrolimus Information for patients about using the drug Tacrolimus. Your consultant has recommended you start treatment with tacrolimus. This leaflet has been developed to provide you with additional

More information

Annex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications

Annex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications Annex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1. Patients with known hypersensitivity to cephalosporin

More information

The management of chronic urticaria in primary care for adults and children

The management of chronic urticaria in primary care for adults and children The management of chronic urticaria in primary care for adults and children September Version 2.0 This supersedes version 1.0 Review due in September 2019 Document location DOCUMENT CONTROL Copies of this

More information

AUGMENTIN 125/31 Suspension co-amoxiclav (amoxicillin and clavulanic acid)

AUGMENTIN 125/31 Suspension co-amoxiclav (amoxicillin and clavulanic acid) Package leaflet: Information for the user AUGMENTIN 125/31 Suspension co-amoxiclav (amoxicillin and clavulanic acid) Read all of this leaflet carefully before you start giving your child this medicine

More information

patient group direction

patient group direction ASPIRIN v01 1/8 ASPIRIN PGD Details Version 1.0 Legal category P Staff grades Approved by Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

DALES Anaesthetist Survey

DALES Anaesthetist Survey 1/7 DALES Anaesthetist Survey Thank you for taking part in DALES, a study about drug allergy labels in elective surgical patients. We will ask for your views on some common allergy labels relevant to anaesthetists

More information

National Clinical Guideline Centre Drug allergy Diagnosis and management of drug allergy in adults, children and young people

National Clinical Guideline Centre Drug allergy Diagnosis and management of drug allergy in adults, children and young people National Clinical Guideline Centre NICE clinical guideline 183 Drug allergy Diagnosis and management of drug allergy in adults, children and young people Clinical guideline 183 Appendices A M September

More information

YVONNE POLYDOROU PAEDIATRIC ALLERGY SPECIALIST DIETITIAN

YVONNE POLYDOROU PAEDIATRIC ALLERGY SPECIALIST DIETITIAN YVONNE POLYDOROU PAEDIATRIC ALLERGY SPECIALIST DIETITIAN 08-12-2016 An allergy is the response of the body's immune system to normally harmless substances, such as pollens, foods, and house dust mite.

More information

METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE

METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE OBJECTIVES To

More information

Adverse Drug Reactions (ADRs) Outline

Adverse Drug Reactions (ADRs) Outline Adverse Drug Reactions (ADRs) Outline 1. What are Adverse Drug Reactions (ADRs)? WHAT WHY HOW 2. How important are ADRs and are they preventable? 3. What are the classifications and mechanisms of ADRs?

More information

CAUTION: You must refer to the intranet for the most recent version of this procedural document.

CAUTION: You must refer to the intranet for the most recent version of this procedural document. Procedure for the use of Intravenous Iron Dextran (CosmoFer ) Sharepoint Location Sharepoint Index Directory Clinical Policies and Guidelines General Policies and Guidelines/ Haematology And blood transfusion

More information

Iron treatment for people with chronic kidney disease (CKD)

Iron treatment for people with chronic kidney disease (CKD) Iron treatment for people with chronic kidney disease (CKD) Information for patients Oxford Kidney Unit If you have chronic kidney disease or are receiving peritoneal dialysis (PD) or hospital dialysis

More information

Allergy Medications. Antihistamines. are very safe. Although usually taken as tablets, they may be prescribed as a liquid or syrup for young children

Allergy Medications. Antihistamines. are very safe. Although usually taken as tablets, they may be prescribed as a liquid or syrup for young children The treatments prescribed for allergy control the symptoms and reactions; they do not cure the condition. However, using treatments as prescribed can show a huge change in a patient s health, mood and

More information

Patient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol

Patient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol Patient leaflet: Information for the user Paracetamol Galpharm 500mg tablets paracetamol [For medicines available only on prescription:] Read all of this leaflet carefully before you start taking this

More information

Anaphylaxis: treatment in the community

Anaphylaxis: treatment in the community : treatment in the community Item Type Guideline Authors Health Service Executive Citation Health Service Executive. : treatment in the community. Dublin: Health Service Executive;. 5p. Publisher Health

More information

Pronaxen 250 mg tablet OTC , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Pronaxen 250 mg tablet OTC , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN Pronaxen 250 mg tablet OTC 25.9.2015, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Pronaxen 250 mg is indicated for

More information

CYANS Primary Care Survey

CYANS Primary Care Survey CYANS Primary Care Survey Evaluation report 2013 CONTENTS page 1. Introduction 1 2. Results of the survey 2 3. Diagnosis and management of allergic conditions 2 4. Referral practice in primary care 3 5.

More information

Antimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections

Antimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections Antimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections Version 7.2 PAGL Inclusion Approved at January 2017 PGC APPROVED BY: TRUST REFERENCE: B3/2017 AWP REF: UHL Policies and

More information

Tuberculosis Procedure ICPr016. Table of Contents

Tuberculosis Procedure ICPr016. Table of Contents Tuberculosis Procedure ICPr016 Table of Contents Tuberculosis Procedure ICPr016... 1 What is Tuberculosis?... 2 Any required definitions/explanations... 2 NHFT... 2 Tuberculosis (TB)... 3 Latent TB...

More information

NHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE

NHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE Suffolk Drug & Therapeutics Committee NHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE What is a shared care document? Suffolk D&T operates a traffic light

More information

An Evidenced-Based Approach to the Adult with a Morbilliform Eruption

An Evidenced-Based Approach to the Adult with a Morbilliform Eruption Relatively An Evidenced-Based Approach to the Adult with a Morbilliform Eruption Ben Kaffenberger, MD Assistant Professor, Dermatology Director, Inpatient Dermatology Consult Service Ohio State University

More information

Allergy Status Identification And Documentation

Allergy Status Identification And Documentation Allergy Status Identification And Documentation Basic Medication Safety (BMS) Certification Course King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs Learning

More information

Zinnat can also be used: to treat Lyme disease (an infection spread by parasites called ticks).

Zinnat can also be used: to treat Lyme disease (an infection spread by parasites called ticks). [GlaxoSmithKline Logo] Package Leaflet: Information for the Patient Zinnat Tablets 125 mg and 250 mg cefuroxime Read all of this leaflet carefully before you start taking this medicine because it contains

More information

Following up patients after treatment for anaphylaxis

Following up patients after treatment for anaphylaxis Following up patients after treatment for anaphylaxis Unsworth D J. Following up patients after treatment for anaphylaxis. Practitioner 2012;256 (1749):21-24 Dr David J Unsworth PhD FRCP FRCPath Consultant

More information

Policy for the use of intravenous Iron Dextran (CosmoFer )

Policy for the use of intravenous Iron Dextran (CosmoFer ) Policy for the use of intravenous Iron Dextran (CosmoFer ) Sharepoint Location Clinical Policies and Guidelines Sharepoint Index Directory General Policies and Guidelines Sub Area Haematology and Blood

More information

PRAC recommendations on signals

PRAC recommendations on signals 25 November 2013 EMA/PRAC/693228/2013 Pharmacovigilance Risk Assessment Committee Adopted at the PRAC meeting of 4-7 November 2013 This document provides an overview of the recommendations adopted by the

More information

Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain

Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low

More information

BNSSG Shared Care Guidance Please complete all sections

BNSSG Shared Care Guidance Please complete all sections NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please

More information

Thrombosis and Anticoagulation Team. Warfarin. Information for patients, relatives and carers

Thrombosis and Anticoagulation Team. Warfarin. Information for patients, relatives and carers Thrombosis and Anticoagulation Team Warfarin Information for patients, relatives and carers What is warfarin? Warfarin is an anticoagulant. Anticoagulants are drugs which prevent harmful blood clots forming

More information